CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com
Biocon Biologics  /  News Room  /  Our Stories

OUR STORIES

Brand Stories

Biocon Biologics has demonstrated success and established global credibility with several of its molecules being approved and launched in both developed and emerging markets. The Company is at an important inflection point as it gains commercial success with its first wave of products and invests in long term sustainability through broadening of its pipeline and commercial presence, further expanding manufacturing scale, and two strategic transactions with Serum Institute Life Sciences and Viatris.

You can read about how Biocon Biologics is evolving as a brand as it focuses, invests, competes and wins in the large and growing opportunity from biosimilars worldwide.

Other Stories

Biocon Biologics Reports a Healthy Business Performance in July-September Quarter

Biocon Biologics Reports a Healthy Business Performance in July-September Quarter
Biocon Biologics’ healthy operating performance came on the back of higher sales of its insulins and antibodies in advanced and emerging markets.

More >> 

Biocon Biologics Approaching Closure of Transaction to Buy Out Viatris’ Biosimilars Business

Biocon Biologics Approaching Closure of Transaction to Buy Out Viatris’ Biosimilars Business
With biosimilars gaining ground globally, the timing of Biocon Biologics’ acquisition of Viatris’ global biosimilars business couldn’t have been better.

More >> 

Strategic Alliance with Serum Institute to Impact Global Health

Strategic Alliance with Serum Institute to Impact Global Health
Combining Strengths in biologics and vaccines for making a meaningful impact in fighting infectious diseases.

More >> 

She Inspires

She Inspires

The inspiring tales of our own Women In Science at Biocon Biologics.

More >>

Hope. Now within reach.
Aiming to reach a billion patients worldwide with affordable, lifesaving medicines.

More >> 

Addressing the COVID-19 Pandemic
The Biocon Group addressed the COVID-19 pandemic unitedly with undeterred spirit and unwavering purpose.

More >>

Meeting unmet patient needs Our novel biologics address unmet medical needs across the world.

More >>

Research saves lives We are accelerating drug innovation and development for companies globally.

More >>

The 10-cent answer to diabetes At 10 cents a day, our insulin is a game changer in the developing world.

More >>

People Stories

Ankur Bhatnagar, our General Manager for Science and Technology Innovation, talks about how he and his team overcome challenges in designing production processes.

More >>

Sivanandam K, Our Global Program Head – Program Management, Sivanandam highlights how Program Management has evolved since its inception in 2009.

More >>

Deepa Mohan, Our Senior Scientific Manager – R&D, she is a functional lead, highlights the Biocon culture, that is primarily based on innovation.

More >>

Anita Rao, Our Project Group Lead – R&D, she is an analytical lead for four of the insulin analog, She highlights the Biocon culture, that is primarily based on innovation.

More >>

Patient Stories

Pooja Hurkat’s struggle with TYPE 1 diabetes

More >> 

Meet Mrs Kumudha Raju just one of the many women fighting HER2-Positive breast cancer

More >>

Neelam’s fight against ascites and ovarian cancer

More >>

Share